MDM2 Amplification in Malignant Peripheral Nerve Sheath Tumors Correlates With p53 Protein Expression

ARUP Institute for Clinical and Experimental Pathology, ARUP Laboratories, Salt Lake City, Utah, USA.
Archives of pathology & laboratory medicine (Impact Factor: 2.84). 01/2012; 136(1):95-9. DOI: 10.5858/arpa.2010-0729-OA
Source: PubMed


MDM2 is known to be abnormally upregulated in a variety of human neoplasms, secondary to gene amplification. Assessment of MDM2 amplification is most useful clinically for separating lipomas (nonamplified) from atypical lipomatous neoplasms or well-differentiated liposarcomas (amplified). MDM2 amplification occurs in approximately 7% of all human neoplasms. In this study, we sought to determine the utility of MDM2 amplification for the separation of benign (schwannomas) and malignant peripheral nerve sheath tumors (MPNSTs). The expression of p53 was correlated with MDM2 amplification because early studies have indicated that MDM2 is rarely amplified in MPNSTs that express p53.
To determine the percentage of MPNSTs with MDM2 amplification and the specificity of MDM2 amplification for malignancy in nerve sheath tumors.
Fifteen MPNSTs, 14 neurofibromas, and 15 schwannomas were obtained from the files of the Department of Pathology. These cases underwent fluorescent in situ hybridization analysis for the presence of MDM2 amplification. Assessments were also made for cellularity (low or high), percentage of cells staining positively for p53 and MDM2 protein, and percentage of cells staining with MIB-1.
Of 15 MPNSTs, 3 (20%) demonstrated amplification of the MDM2 gene. No neurofibromas or schwannomas demonstrated MDM2 amplification. All 3 MDM2 -amplified MPNSTs were positive for p53. Correlation of MDM2 amplification status and p53 immunoreactivity was statistically significant (P  =  .004).
The low frequency (20%) of MDM2 amplification in our series of MPNSTs demonstrates that MDM2 fluorescent in situ hybridization has limited diagnostic value for the separation of benign schwannomas and MPNSTs. Our study demonstrated a positive correlation (P  =  .004) between MDM2 amplification and p53 expression.

4 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND:: Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the gastrointestinal tract. Clinical behavior is best predicted by size and mitotic count (risk index). KIT and platelet-derived growth factor receptor α (PDGFRA) mutations have therapeutic and prognostic value but few other prognostically significant molecular markers have been identified. We investigated the prognostic value of p53 protein expression and MDM2 gene amplification in a series of GISTs. METHODS:: Thirty-five GISTs were tested for KIT and PDGFRA mutations, p53 protein expression (high >10% positive by immunohistochemistry) and MDM2 gene amplification (ratio >1.8). Mitotic index (>5/50 HPF), MDM2 amplification status, p53 protein expression, tumor size, and KIT/PDGFRA mutational status were correlated with clinical outcome. RESULTS:: Only a single (3%) GIST was amplified for MDM2. p53 protein expression, mitotic index, and KIT/PDGFRA mutations did not correlate with recurrence or metastasis (P=0.20, 0.50, and 0.08, respectively) but tumor size did (P=0.04). Risk assessment (size and mitotic index) showed a weak association with clinical behavior (P=0.19). CONCLUSIONS:: MDM2 amplification is uncommon in GISTs. Although high p53 expression occurred in 35% of cases, it did not correlate with clinical behavior. Only GIST size predicted clinical outcome.
    No preview · Article · Oct 2012 · Applied immunohistochemistry & molecular morphology: AIMM / official publication of the Society for Applied Immunohistochemistry
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: There is much ambiguity surrounding the diagnosis of nerve sheath tumors, including atypical neurofibroma and low-grade MPNST, and yet, the distinction between these entities designates either benign or malignant behavior and thus carries presumed profound prognostic importance that often guides treatment. This study reviews the diagnostic criteria used to designate atypical neurofibroma from low-grade MPNSTs and reviews existing literature the natural history of each of these tumors to see if the distinction is, in fact, of importance.
    Full-text · Article · Jun 2013 · Cancers
  • [Show abstract] [Hide abstract]
    ABSTRACT: Enormous efforts have been made to explore small molecules that interfere with the TGF-β signaling pathway, so as to inhibit EMT and the cancer metastasis, but few agents have been identified. In this study, we demonstrated that Nutlin-3 could abolish the down-regulation of E-cadherin induced by TGF-β1 in p53-deficient cancer cells. Further studies revealed that Nutlin-3 prohibited EMT by blocking the phosphorylation of Smad2/3, resulting in the decreased transcription of Snail/Slug. In addition, Nutlin-3 suppressed the motility of cancer cells, and potentiated the anti-proliferative activity of Gefitinib and Lapatinib. Collectively, Nutlin-3 could inhibit EMT and enhance the anti-cancer activity of EGFR inhibitors by interfering with the canonical TGF-β1-Smad-Snail/Slug axis, in a p53-independent manner.
    No preview · Article · Aug 2013 · Cancer letters
Show more